23rd week of 2015 patent applcation highlights part 8 |
Patent application number | Title | Published |
20150150887 | PHARMACEUTICAL COMPOSITIONS COMPRISING ESTETROL DERIVATIVES FOR USE IN CANCER THERAPY - The present invention relates to a method of treating or preventing estrogen-suppressed tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: | 2015-06-04 |
20150150888 | COMBINATION OF SELECTIVE PROGESTERONE-RECEPTOR MODULATORS AND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS - The invention relates to a pharmaceutical composition combining a selective progesterone receptor modulator (SPRM), such as ulipristal acetate, and one or more non-steroidal anti-inflammatory compounds, in particular in a method of regular contraception, or in emergency or on-demand contraception. | 2015-06-04 |
20150150889 | COMPOSITIONS COMPRISING TRAMADOL AND CELECOXIB IN THE TREATMENT OF PAIN - The present invention relates to pharmaceutical compositions comprising tramadol and celecoxib and their uses as medicaments or analgesics, more particularly for the treatment of severe to moderate pain with an inflammation component. | 2015-06-04 |
20150150890 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS - The present invention includes novel compounds and pharmaceutically acceptable formulations of said compounds which exhibit antibiotic activity against microorganisms bearing a guanine riboswitch that controls the expression of the guaA gene, including organisms which are resistant to certain antibiotic families, and which are useful as antibacterial agents for treatment or prophylaxis of bacterial infections in animals or in humans, in particular but not limited to infections of the mammary gland, or their use as antiseptics, agents for sterilization or disinfection. | 2015-06-04 |
20150150891 | Surfactant Lipids, Compositions Thereof, and Uses Thereof - The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions. | 2015-06-04 |
20150150892 | METHODS AND PRODUCTS RELATED TO LUNG CANCER - The invention relates to methods and related products for treatment and determining modes of treatment for cancer. Preferably the methods relate to the inhibition of the NF-κB pathway in lung cancer. | 2015-06-04 |
20150150893 | ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION - This invention relates to novel andrographolide analogs of formula I that are useful for the treatment, prevention and/or amelioration of human diseases of viruses and cancers. This invention also relates with their pharmaceutical compositions, preparative methods and applications. | 2015-06-04 |
20150150894 | Chemosensory Receptor Ligand-Based Therapies - Provided herein are methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions comprising chemosensory receptor ligands. Also provided herein are chemosensory receptor ligand compositions and the preparation thereof for the methods of the present invention. | 2015-06-04 |
20150150895 | PHARMACEUTICAL ANTI-INFECTIVE COMPOSITION FOR INHALATION - An anti-infective composition for inhalation, containing, at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof; and an effective amount of a biofilm modifier which is a macrolide compound or salt thereof. | 2015-06-04 |
20150150896 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS - Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period. | 2015-06-04 |
20150150897 | METHODS OF TREATING HEPATITIS C VIRUS INFECTION IN SUBJECTS WITH CIRRHOSIS - Methods of treating hepatitis C virus infection in a subject with cirrhosis comprising administering to the subject an effective amount of Compound 1. | 2015-06-04 |
20150150898 | NUTRITIONAL PRODUCTS AND METHODS OF IMPROVING EXERCISE PERFORMANCE AND REDUCING EXERCISE INDUCED IMPAIRMENT OF IMMUNE FUNCTION - Nutritional products comprising a nucleotide component and optionally, a carbohydrate component, a protein component and a polyunsaturated fatty acid component are disclosed. The products can be in various product forms, including solid and liquid forms, such as drinks, bars, and gels. Also disclosed are methods for inhibiting exercise-induced impairment of immune system functioning and for improving exercise performance by administration of compositions containing nucleotides. | 2015-06-04 |
20150150899 | Isoform of Bruton's Tyrosine Kinase (BTK) Protein - The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAI, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumor pathologies. Also described is a method for the determination of the drug resistance in tumor cells, as well as a method for the identification of tumor stem cells. | 2015-06-04 |
20150150900 | High Molecular Weight Heparosan Polymers and Methods of Production and Use Thereof - High molecular weight heparosan polymers are described, as are methods of producing and using the high molecular weight heparosan polymers. | 2015-06-04 |
20150150901 | Co-Therapy for Diabetic Conditions - Methods of treating diseases such as diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbAlc levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof. Drug products including a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof, in combination are also disclosed. | 2015-06-04 |
20150150902 | COMPOSITION AND METHOD FOR PROMOTING JOINT AND BONE HEALTH - The present invention provides compositions comprising silicon and at least one other joint health ingredient such as glucosamine, chondroitin, hyaluronic acid, collage, etc. as well as methods for making and using the same. | 2015-06-04 |
20150150903 | COMPOSITIONS COMPRISING BIOMEMBRANE SEALING AGENT FOR TREATMENT OF NEURONAL INJURY, AND METHODS OF USE - The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant. | 2015-06-04 |
20150150904 | DIETARY SUPPLEMENT COMPOSITION AS A PROPHYLACTIC AND TREATMENT FOR SKIN DISEASES SUCH AS ECZEMA AND PSORIASIS AND THE LIKE AND METHOD OF TREATMENT - A dietary supplement composition as a prophylactic and treatment for skin diseases such as eczema and psoriasis and the like, the composition comprising a phase II liver detoxification component having glycine, and magnesium, wherein glycine and magnesium are present in the supplement composition in a ratio of between about 20:1 and 20:8. | 2015-06-04 |
20150150905 | SOLUTION FOR PERITONEAL DIALYSIS - The present invention relates to a solution for peritoneal dialysis, consisting of at least two single solutions which are combined after a heat sterilization and are administered to a patient, the first single solution containing an osmotic and the second single solution containing a buffer, and one of these single solutions or another single solution containing electrolyte salts. The avoidance of a glucose-like degradation as well as hydrolysis during sterilization and storage while maintaining a neutral mixture pH is achieved according to the invention by the osmotic comprising a glucose polymer and/or glucose polymer derivative, and the pH of the first single solution being between 3.5 and 5.0. | 2015-06-04 |
20150150906 | COMPOSITIONS OF HYPOCHLOROUS ACID(HOCl) AND METHODS OF MANUFACTURE THEREOF - The invention generally relates to compositions of hypochlorous acid (HOCl) and methods of manufacture thereof. In certain aspects, the invention provides air-free compositions of HOCl. In other aspects, the invention provides methods of making HOCl that involve mixing together in water in an air-free environment, a compound that generates a proton (H | 2015-06-04 |
20150150907 | COMPOSITIONS OF HYPOCHLOROUS ACID(HOCl) AND METHODS OF MANUFACTURE THEREOF - The invention generally relates to compositions of hypochlorous acid (HOCl) and methods of manufacture thereof. In certain aspects, the invention provides air-free compositions of HOCl. In other aspects, the invention provides methods of making HOCl that involve mixing together in water in an air-free environment, a compound that generates a proton (H | 2015-06-04 |
20150150908 | COMPOSITIONS AND METHODS FOR TREATING SKIN WOUNDS - The invention relates to a composition containing a peroxide, a carbonate source, and a salt. The invention also relates to treating skin wounds using the composition. | 2015-06-04 |
20150150909 | ANTI-GLYCATION METHODS AND COMPOSITIONS - The present invention comprises compositions that provide anti-glycation activity comprising a mineral extract composition or a mogroside/mineral extract composition or a mogroside composition. Such compositions are useful for methods of preventing, treating and inhibiting the effects of glycation in the body. The methods of the present invention comprise use of anti-glycation composition for the treatment and prevention of glycation related conditions including diabetes, atherosclerosis, arthritis, mental conditions and vision impairment. | 2015-06-04 |
20150150910 | SUBSTITUTE THERAPY FOR GLUCOCORTICOIDS - The present invention relates to a pharmaceutical composition comprising glucocorticoid (GC)-induced human monocytes, and optionally a pharmaceutically acceptable carrier. | 2015-06-04 |
20150150911 | METHODS TO REDUCE ADVERSE EVENTS CAUSED BY PHARMACEUTICAL PREPARATIONS COMPRISING PLASMA DERIVED PROTEINS - The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction said plasma fraction comprising antithrombin III wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine protease per ml of the plasma fraction. | 2015-06-04 |
20150150912 | CEACAM1 MEDIATED PROTECTIVE IMMUNITY - The presently described technology relates to the modulation of specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, the present technology relates to the supression of immune responses in a targeted fashion, by increasing the functional concentration of the CEACAM1 protein in a target tissue to create a localized protective immunity for the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. | 2015-06-04 |
20150150913 | Compositions and Methods for Preventing Cardiac Arrhythmia - Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject. | 2015-06-04 |
20150150914 | Compositions and Methods for Preventing Cardiac Arrhythmia - Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject. | 2015-06-04 |
20150150915 | Methods for treating ocular contusion and blunt injury and traumatic injury to the optic nerve - The invention is directed to methods for treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve. The invention is further directed to treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve by administering to a subject suffering from such conditions Amnion-derived Cellular Cytokine Solution (ACCS), including novel immediate-release, targeted-release, and sustained-release (SR) ACCS compositions (referred to herein as “SR-ACCS” compositions) and/or and Amnion-derived Multipotent Progenitor (AMP) cell compositions. Such administration includes intranasal administration of ACCS and/or AMP cells. | 2015-06-04 |
20150150916 | INSULIN RESISTANCE-IMPROVING AGENT CONTAINING EGGSHELL MEMBRANE COMPONENT, AND COMPOSITION USING THE SAME - To provide an insulin resistance-improving agent, and the application thereof. The insulin resistance-improving agent contains an eggshell membrane component, for example, an eggshell membrane-containing powder or a soluble eggshell membrane component. Further, the eggshell membrane-containing powder to be used is a fine powder, and preferably has a volume average particle size of 6 μm or less, and/or a volume maximum particle size of 20 μm or less, but these particle sizes are not limited to the values. | 2015-06-04 |
20150150917 | Selection and Use of Lactic Acid Bacteria Preventing Bone Loss in Mammals - The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs. | 2015-06-04 |
20150150918 | Method for treating or preventing heart diseases - This invention discloses a method for treating or preventing heart diseases by using a probiotic composition. The method for treating or preventing heart diseases comprises administering to a subject an effective amount of a probiotic composition to prevent the myocardial cells from myocardial hypertrophy, fibrosis and apoptosis, wherein the probiotic composition comprising | 2015-06-04 |
20150150919 | COMPOSITIONS COMPRISING COCKTAILS OF ANTIBACTERIAL PHAGES AND USES THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS - The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular diabetic foot infections. More specifically, the present invention is directed to novel cocktails of bacteriophage strains F44/10, F1 25/10, F770/05, F510/08, F1 245/05, and/or variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including cutaneous ulcers associated with diabetic foot infections, caused by, e.g., | 2015-06-04 |
20150150920 | Use of Mutant Herpes Simplex Virus-2 for Cancer Therapy - The present invention is directed to the composition and use of a modified Herpes Simplex Virus Type 2 (HSV-2) as a medicament in the treatment of cancer. The modified HSV-2 has fusogenic activity, and comprises a modified/mutated ICP10 polynucleotide encoding a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity. | 2015-06-04 |
20150150921 | FUSARIUM AND OTHER PATHOGENIC FUNGI AND MYCOTOXIN BIOCONTROL - The present disclosure relates to a novel ascomyceteous fungus, | 2015-06-04 |
20150150922 | COMPOSITION FOR USE IN AROMATHERAPY, AROMA MEDICINE AND AROMATOLOGY - The present invention refers to a composition for aromatherapy, as well as to its use as a medicine and in aromatherapy for the treatment of troublesome emotions. The composition includes 0.01 to 0.125 vol-% of an active composition and 0.1 to 99.99 vol-% of a transport composition and optionally a carrier oil and/or an alcohol. The active composition contains a mixture of 80 to 120 different essential oils and an alcohol in a volume ratio of 1:500 to 1:5,000 of oils:alcohol. The transport composition is made of one or more essential oils. The treatment involves smelling of the composition simultaneously with a troublesome emotion. In this way, the emotion is sustainably relieved. | 2015-06-04 |
20150150924 | WOUND HEALING COMPOSITE WITH A FUNCTION OF PROMOTING THE GROWTH OF GRANULATION TISSUES - A wound healing composite with a function of promoting the growth of granulation tissues includes a substrate extracted from a plant and a base, and the substrate includes a loniceraiaponica extract, a mugwort extract, and ginkgo, and both loniceraiaponica extract and ginkgo have a weight percentage ranging from 0.28% to 3.5%. The wound healing composite can effectively promote the growth of granulation tissues, and loniceraiaponica, mugwort, ginkgo and other ingredients are extracts of natural plants, and thus the wound healing composite has a low drug resistance and does not have the side effect of drug allergy or the doubt leading to skin cancer. | 2015-06-04 |
20150150925 | WOUND HEALING COMPOSITE WITH A FUNCTION OF PROMOTING THE GROWTH OF GRANULATION TISSUES - A composite with antibacterial and antipruritic functions includes a first substrate extracted from a plant, a second substrate and a base, and the first substrate includes a loniceraiaponica extract and an acanthopanax extract, and both loniceraiaponica extract and acanthopanax extract have a weight percentage ranging from 0.75 to 1.33, and the composite can effectively restrain the itch caused by skin pustules, folliculitis, and mosquito bites, and achieve the moisturization and antipruritic and anti-dander effects for mitigating the symptoms caused by | 2015-06-04 |
20150150926 | COMPOSITE WITH ANTIBACTERIAL AND ANTIPRURITIC FUNCTIONS - A composite with antibacterial and antipruritic functions includes a first substrate extracted from a plant, a second substrate and a base, and the first substrate includes a loniceraiaponica extract and an acanthopanax extract, and both loniceraiaponica extract and acanthopanax extract have a weight percentage ranging from 0.75 to 1.33, and the composite can effectively restrain the itch caused by skin pustules, folliculitis, and mosquito bites, and achieve the moisturization and antipruritic and anti-dander effects for mitigating the symptoms caused by | 2015-06-04 |
20150150927 | Composition for improving lactation - Disclosed is a novel composition effective to improve lactation and milk production in an animal. In some embodiments the composition comprises a fiber-depleted fraction derived from fenugreek in combination with additives that synergistically improve the effective of the composition. Additives that enhance the effect of the fenugreek fraction can include apple cider vinegar, fennel seed powder, saw palmetto berry extract, kelp powder, and methylsulfonylmethane. | 2015-06-04 |
20150150928 | COMPOSITION FOR PREVENTING AND TREATING AIDS AND PREPARATION METHOD THEREOF - The present invention relates to a pharmaceutical composition made from the following raw materials or from water and/or alcohol extracts of the following raw materials in parts by weight: 5 to 200 parts of Ganoderma, 5 to 150 parts of Radix Panacis Quinquefolii or Radix Et Rhizoma Ginseng, 1 to 90 parts of fermented | 2015-06-04 |
20150150929 | USE OF ESSENTIAL OIL OF OREGANO OR OF ROSEWOOD, OR CONSTITUENTS THEREOF, IN THE COSMETIC TREATMENT OF KERATOSES - The present invention concerns various cosmetic uses of compositions comprising an essential oil or one of its constituents, preferably a major constituent, in the targeted treatment and prevention of benign keratoses, and more particularly keratoses induced by solar radiation on the skin of a subject. More particularly, the present invention concerns compositions based on the essential oil of oregano or of rosewood, or on linalool, thymol or carvacrol. The present invention also concerns therapeutic applications of a composition as described in the prevention or targeted treatment of actinic keratoses, essentially for prophylactic purposes. | 2015-06-04 |
20150150930 | ARO-HONEY STARCH GEL FOR WOUNDS, BURNS AND SKIN CARE - Compositions comprising honey, starch hydrolysate, and clove EO are described. The compositions can also comprise one or more pharmaceutically acceptable diluents and/or excipients. Also described herein are methods for treating a wound comprising administering to the wound an effective amount of the present composition. The wound can be a burn, bed sore or a diabetic ulcer. The wound can also be infected. | 2015-06-04 |
20150150931 | Method to facilitate healing of wounds - A method for treating wounds utilizing a dry powder mixture created using dry flour. The wound healing dry powder is created through the method of first heating dry flour over heat for a sufficient amount of time to undergo a chemical change wherein the flour changes color. In this method, the brown substance is applied directly to the wound each day for a sufficient amount of time until the wound heals. | 2015-06-04 |
20150150932 | SOLUABLE FIBER DIGESTIVE THERAPY AND DELIVERY SYSTEM - A delivery system in the form of a soluble fiber formulation for therapeutic supplement and medication delivery includes approximately 70%-80% water, 14%-48% pumpkin powder, 0.5%-2.5% oat fiber powder and 0.4%-1.0% psyllium powder. The formulation also includes 0.6%-0.7% sodium bisulfate 0.0%-0.5% flavoring and 0.1%-0.25% potassium sorbate. The ingredients are mixed together to form a puree consistency. | 2015-06-04 |
20150150933 | METHOD AND COMPOSITIONS FOR IMPROVING A RESPONSE TO A METABOLIC STRESS - The present disclosure relates to methods and compositions for improving a response to a metabolic stress. Certain embodiments provide a method of improving a response to a metabolic stress in a subject. The method comprises administering to a mucosal membrane of the subject an effective amount of an autolysate from rootlets of a barley plant of the species | 2015-06-04 |
20150150934 | PHARMACEUTICAL COMPOSITION HAVING PREVENTATIVE OR TREATMENT EFFECT ON INFLAMMATORY BOWEL DISEASES COMPRISING STEMONAE RADIX EXTRACT - The present invention relates to a pharmaceutical composition, which comprises a Stemonae Radix extract, for preventing or treating the occurrence of inflammatory bowel diseases due to cigarette smoke, a method for preventing or treating the occurrence of inflammatory bowel diseases using the composition, a method for suppressing the expression of inflammatory cytokines using the composition, and to a food composition, which comprises the Stemonae Radix extract, for preventing or treating the occurrence of inflammatory bowel diseases due to cigarette smoke. The pharmaceutical composition comprising the Stemonae Radix extract, according to the present invention, reduces the level of MMP12 expression that is known to destroy IL-1β, TNF-α, and IL-6, which are inflammatory cytokines that accompany the inflammatory bowel diseases, and elastin and collagen, and can suppress decrease in the number of lactobacilli in the intestine, and thus can be widely used in developing a safe and effective inflammatory bowel diseases treating agent. | 2015-06-04 |
20150150935 | PERIPHERAL KAPPA RECEPTOR AGONISTS FOR REDUCING PAIN AND INFLAMMATION - A method of treating of a mammalian subject suffering from an inflammatory disease or condition by administering a peripherally-restricted kappa opioid receptor agonist for reducing the inflammation is provided. The peripherally-restricted kappa opioid receptor agonist can include a peptide and the peptide can include D-amino acids. Administration of peripherally-restricted kappa opioid receptor agonists results in lowering of serum levels of pro-inflammatory cytokines and elevation of levels of anti-inflammatory cytokines. | 2015-06-04 |
20150150936 | USE OF DES-ASPARTATE-ANGIOTENSIN I TO TREAT PATIENTS EXHIBITING HIGH BLOOD GLUCOSE LEVELS OR GLUCOSE-INDUCED PANCREATIC BETA CELL DEATH - The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions. | 2015-06-04 |
20150150937 | POLYMERIC DELIVERY FORMULATIONS OF LEUPROLIDE WITH IMPROVED EFFICACY - The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate. | 2015-06-04 |
20150150938 | PHARMACEUTICAL FORMULATIONS - Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way. | 2015-06-04 |
20150150939 | Apolipoprotein Mixtures - The present invention provides a pharmaceutical composition comprising a mixture of apolipoproteins. Methods for elevating HDL levels are also provided as are methods for the treatment and prevention of cardiovascular diseases and disorders, inflammation and metabolic diseases. | 2015-06-04 |
20150150940 | TREFOIL FAMILY FACTOR PROTEINS AND USES THEREOF - The invention provides for methods for treating an inflammatory disease of the digestive system in a subject by administering a trefoil family molecule. The invention provides for methods for treating a digestive system cancer in a subject by administering a trefoil family molecule. The invention provides for methods for cell proliferation in a subject by administering a trefoil family molecule. | 2015-06-04 |
20150150941 | CHRONIC LYMPHOCYTIC LEUKEMIA PROGNOSIS AND TREATMENT - Provided herein are methods for identifying a subject afflicted with chronic lymphocytic leukemia who is responsive to treatment with a chemotherapeutic agent by detecting the presence or absence of at least one APOE4 allele in the subject, the presence of an APOE4 allele identifying the subject as responsive to the treatment. Also provided are methods of treating a subject afflicted with chronic lymphocytic leukemia, including administering an estrogenic agent, an androgen withdrawal agent, an apoE4 peptide or mimetic thereof, and/or a chemotherapeutic agent in an amount effective to treat said chronic lymphocytic leukemia. Methods of determining a prognosis for a patient diagnosed with chronic lymphocytic leukemia are also provided. In addition, methods for stratifying a subject into a subgroup of a clinical trial and methods for identifying a patient in a clinical trial of a treatment for chronic lymphocytic leukemia are herein provided. | 2015-06-04 |
20150150942 | METHODS FOR EXTRACTING PLATELETS AND COMPOSITIONS OBTAINED THEREFROM - This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same. | 2015-06-04 |
20150150943 | USE OF SDF-1 TO IMPROVE ISCHEMIC MYOCARDIAL FUNCTION - A method is provided for increasing trafficking of endothelial progenitor cells to an ischemic myocardium in a subject's heart comprising administering to the subject's heart an amount of Stromal-Derived Factor-1 (SDF-1). | 2015-06-04 |
20150150944 | Vault Complexes for Cytokine Delivery - The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer. | 2015-06-04 |
20150150945 | Modifying Macrophage Phenotype for Treatment of Disease - The present invention provides compositions and methods for modulating one or more phenotypes of a macrophage-related cell, e.g., a macrophage. The invention further provides methods of treating disease by modulating macrophage phenotype. Representative phenotypes include pro-inflammatory, anti-inflammatory, immunogenic, tolerogenic, tissue-destructive, tissue restorative, cytotoxic, migratory, bone-resorbing, pro-angiogenic, anti-angiogenic, suppressor, antigen presentation, or phagocytic. Representative diseases include atherosclerosis, arthritis, and multiple sclerosis. | 2015-06-04 |
20150150947 | TREATING INFLAMMATION USING SERELAXIN - The present disclosure relates to methods of treating inflammation in a subject. Particularly, the disclosure provides methods for treating inflammation by administering pharmaceutically active serelaxin in order to increase a soluble marker associated with reducing inflammation. Further encompassed in the present disclosure are method for treating inflammatory disorders and kits for administering pharmaceutically active serelaxin to subjects suffering from such disorders. | 2015-06-04 |
20150150948 | METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT - Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA | 2015-06-04 |
20150150949 | TOPICAL THERAPEUTIC FORMULATIONS - The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites. | 2015-06-04 |
20150150950 | METHODS AND PRODUCTS RELATING TO GSK3 REGULATION - The invention relates to methods and compositions for regulation of GSK3β activity. The invention provides phosphorylated GSK3β polypeptides and antibodies that recognize such polypeptides The invention further includes methods for treating disorders that are associated with elevated or reduced GSK3β activity. | 2015-06-04 |
20150150951 | PHARMACEUTICAL COMPOSITION COMPRISING BEE VENOM-PHOSPHOLIPASE A2 (BV-PLA2) FOR TREATING OR PREVENTING DISEASES RELATED TO DEGRADATION OF ABNORMAL REGULATORY T CELL ACTIVITY - The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases. | 2015-06-04 |
20150150952 | METHODS FOR TREATING CACHEXIA - The invention provides a method for treating cachexia, weakness, fatigue, and/or fever in a subject, the method comprising administering to the subject an effective amount of angiogenin or an angiogenin agonist. The method is particularly applicable to the prevention or treatment of cancer cachexia. | 2015-06-04 |
20150150953 | PHARMACEUTICAL COMPOSITION ADAPTED FOR ORAL ADMINISTRATION AND THE PROCESS FOR ITS PREPARATION, FOR THE PREVENTION AND TREATMENT OF IRRITABLE BOWEL SYNDROME, BASED ON AN INTESTINAL MOTILITY MODIFIER AND a-D-GALACTOSIDASE - The invention relates to a pharmaceutical formulation or composition in the form of a tablet, coated tablet, capsule or powder tor reconstitution, for use in irritable bowel syndrome, comprising an intestinal motility modifier and enzyme α-D-galactosidase. | 2015-06-04 |
20150150954 | TREATMENT OF INFLAMMATORY SKIN DISORDERS - The invention relates to methods of using an effective amount of activated protein C (APC) to treat an individual for a skin disorder characterised by the presence of hyperproliferative keratinocytes. | 2015-06-04 |
20150150955 | Enzyme Delivery Systems and Methods of Preparation and Use - This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders. | 2015-06-04 |
20150150956 | EPITOPE COMPOSITION - A pharmaceutical composition for sublingual, buccal or enteric administration comprising at least one substance obtainable by hydrolysis with chymotrypsin of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease. | 2015-06-04 |
20150150957 | Consensus Prostate Antigens, Nucleic Acid Molecule Encoding The Same And Vaccine And Uses Comprising The Same - Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided. | 2015-06-04 |
20150150958 | Compositions And Methods For Treatment Of Microbial Infections - The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions. | 2015-06-04 |
20150150959 | BACTERIAL BIOFILM MATRIX AS A PLATFORM FOR PROTEIN DELIVERY - Some aspects of this disclosure provide engineered exopolysaccharide-associated proteins, engineered bacteria expressing such proteins, and engineered biofilms comprising such proteins. Some aspects of this disclosure provide methods for engineering exopolysaccharide-associated proteins, and for the generation of engineered bacteria and biofilms expressing or comprising such proteins. Some aspects of this disclosure provide compositions and methods useful for the generation of vaccines and the vaccination of subjects, for delivering molecules of interest to a target site, for example, a surface, for purification of molecules of interest, for example, from bioreactors comprising engineered bacteria as provided herein, and for bioremediation applications, such as the cleanup of environmental pollutants. | 2015-06-04 |
20150150960 | PROTECTION AGAINST DENGUE VIRUS AND PREVENTION OF SEVERE DENGUE DISEASE - The invention provides uses, methods and compositions for eliciting, stimulating, inducing, promoting, increasing, or enhancing an anti-Dengue virus T cell response in a subject. | 2015-06-04 |
20150150961 | COMPOSITIONS AND METHODS FOR RAPID IMMUNIZATION AGAINST DENGUE VIRUS - Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration. | 2015-06-04 |
20150150962 | Chicken Astrovirus Responsible for Runting Stunting Syndrome - The present invention includes isolated astroviruses capable of reproducing the full Runting Stunting Syndrome (RSS) disease spectrum in poultry, including a chicken astrovirus isolated from the gut of chickens (CkAstV-Gut), a cell culture chicken astrovirus CkAstV-p5, and a chicken astrovirus isolated after back passage in chicken (CkAstV-p5-Ckp5), and infected cell lines, cell culture supernatants, polynucleotide sequences, vectors, polypeptides, compositions, and vaccines thereof. The present invention also includes diagnostic methods based on such isolated viruses and infected cell lines, cell culture supernatants, polynucleotide sequences, vectors, and polypeptides thereof, and methods of protecting poultry, including chickens, against RSS by the administration of such isolated viruses and infected cell lines, cell culture supernatants, polynucleotide sequences, vectors, polypeptides, compositions, and vaccines thereof. | 2015-06-04 |
20150150963 | VACCINATION WITH INTERLEUKIN-4 ANTAGONISTS - The invention relates to methods for inducing an antigen-specific immune response, methods for increasing the avidity of immune cells for an antigen, methods for increasing the number of immune cells specific for an antigen, methods of preventing or treating infection and methods of vaccinating, the methods comprising administering an interleukin-4 receptor (LL-4R) antagonist in combination with an antigen, in particular HIV-1 antigens selected from a gag, pol, or env. | 2015-06-04 |
20150150964 | HERPESVIRUS COMPOSITIONS AND RELATED METHODS - The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compositions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization. | 2015-06-04 |
20150150965 | Adjuvant - The present invention is based on the identification of the adjuvant properties of inorganic (metal/metal oxide) nanoparticles. As such, the invention provides an adjuvant comprising, consisting or consisting essentially of inorganic nanoparticle. The invention also provides compositions and vaccines comprising the same as well as methods which exploit the adjuvant inorganic nanoparticles. | 2015-06-04 |
20150150966 | IMMUNOGENIC COMPOSITION AND USES THEREOF - The present invention provides an immunogenic composition comprising an antigen and a dendritic cell targeting component. A charged group is covalently attached to a dendritic cell ligand and is electrostatically associated with the dendritic cell targeting component. | 2015-06-04 |
20150150967 | COMPOSITION COMPRISING A COLLOIDAL SYNTHETIC BIORESORBABLE VECTOR AND A VIRAL VECTOR - A method of vaccination against a viral, bacterial or non-infectious disease includes administering an effective dose of a prime vaccine and then an effective dose of a boost vaccine. Each one of the prime vaccine and the boost vaccine includes an active principle. The prime vaccine includes, as the active principle, a colloidal synthetic bioresorbable vector that includes at least one protein substance. The boost vaccine includes, as the active principle, a viral vector that includes at least one nucleotide sequence which codes for a protein substance corresponding to the at least one protein substance of the synthetic vector. | 2015-06-04 |
20150150968 | USE OF CD28-SPECIFIC MONOCLONAL ANTIBODIES FOR PRODUCING A PHARMACEUTICAL COMPOSITION FOR TREATING VIRUS INFECTIONS - The invention relates to the use of monoclonal antibodies which are specific for CD28 and activate the T lymphocytes of several up to all subgroups without the occupation of an antigen receptor of the T lymphocytes and which therefor activate said lymphocytes in an antigen unspecific manner or the invention relates to the use of an analogue thereof for producing a pharmaceutical composition in the form of a preparation or a preparation packet for treating virus infections in humans or lower warm-blooded animals having infected T lymphocytes. The pharmaceutical composition additionally contains a virus inhibitor. The invention also relates to a corresponding pharmaceutical composition and a treatment plan including the pharmaceutical composition. | 2015-06-04 |
20150150969 | CHIMERIC AND HUMANIZED ANTI-HISTONE ANTIBODIES - The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g., SLE), atherosclerosis, arthritis, rheumatoid arthritis, edema, sepsis, septic shock, hyperinflammatory disorder, infectious disease, inflammatory disease, immune dysregulatory disorder, GVHD, transplant rejection, atherosclerosis, asthma, a coagulopathy, myocardial ischemia, thrombosis, nephritis, inflammatory liver injury, acute pancreatitis, ischemia-reperfusion injury, stroke, cardiovascular disease, and burn. | 2015-06-04 |
20150150970 | GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN ErbB ANTAGONIST CANCER THERAPY - The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody. | 2015-06-04 |
20150150971 | SONOSENSITIVE LIPOSOME, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND METHOD OF DELIVERING ACTIVE AGENT TO SUBJECT USING THE SONOSENSITIVE LIPOSOME - Provided is a liposome comprising a lipid bilayer and a sonosensitizer that is disposed in and/or on the lipid bilayer, wherein the sonosensitizer self-assembles to form aggregates when exposed to ultrasound; and a method of efficiently delivering an active agent to a target site in the body of a subject using the sonosensitive liposome. | 2015-06-04 |
20150150972 | USE OF AMINOLEVULINIC ACID AND DERIVATIVES THEREOF - The invention provides the use of a photosensitiser which is a derivative (e.g. an ester) of 5-aminolevulinic acid (5-ALA), or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: | 2015-06-04 |
20150150973 | MAGNESIUM PHOSPHATE GELS - There is provided a magnesium phosphate gel comprising water as a dispersing phase and phosphate ions (PO | 2015-06-04 |
20150150974 | TOPICAL COMPOSITIONS OF AQUEOUS GEL TYPE IN THE FORM OF A HOMOGENEOUS SUSPENSION OF AN ACTIVE PRINCIPLE OF THE RETINOID CLASS CONTAINING AT LEAST ONE HYDROPHOBIC SILICA - Aqueous-gel type topical compositions are described. The compositions can be in the form of a homogeneous suspension of an active principle of the class of retinoids including at least one hydrophobic silica, the active principle preferably having general formula (I), and more specifically being 3″-tert-butyl-4′-(2-hydroxy-ethoxy)-4″-pyrrolidin-1-yl-[1,1′3′,1″]-terphenyl-4-carboxylic acid. Also described, is the preparation mode thereof and the use of same in the treatment of dermatological conditions. | 2015-06-04 |
20150150975 | TRANSDERMAL CANCER ANTIGEN PEPTIDE PREPARATION - The invention enables more efficient CTL induction by applying a transdermal preparation containing a WT1 protein-derived cancer antigen peptide and an ether-type additive, which is liquid at 20° C., to a WT1 protein-derived cancer antigen peptide. The ether-type additive is represented by the formula (1): R | 2015-06-04 |
20150150976 | PHENYLEPHRINE-CONTAINING LIQUID FORMULATIONS - An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1. | 2015-06-04 |
20150150977 | HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING - The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions. | 2015-06-04 |
20150150978 | DOSAGE THAT IS SAFEGUARDED FROM ABUSE - The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form. | 2015-06-04 |
20150150979 | PHARMACEUTICAL FORMULATION - The present invention relates to methods and means for reducing the viscosity of a pharmaceutical formulation comprising an antibody or other therapeutic protein at a high concentration. The present invention provides a liquid pharmaceutical formulation comprising an antibody at a high concentration with reduced viscosity that does not impede processing or injection of the pharmaceutical formulation. | 2015-06-04 |
20150150980 | METHODS AND COMPOSITIONS FOR TREATING PAIN - Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy. | 2015-06-04 |
20150150981 | ORGANIC-INORGANIC HYBRID SOLID HAVING A MODIFIED OUTER SURFACE - The present invention concerns metal-organic hybrid solids having a modified outer surface. These solids can be used, for example, for the storage and vectoring of molecules of interest such as pharmaceutically active ingredients, compounds of interest in cosmetics and markers, for example contrast agents. These solids have good results in terms of active drug loading capacities, biocompatibility, stability and controlling the release of the active ingredients encapsulated. | 2015-06-04 |
20150150982 | PHARMACEUTICAL FORMULATION FOR A THERAPEUTIC ANTIBODY - The present invention relates to pharmaceutical formulations for a therapeutical antibody, preferably an IgG, said formulation comprising at least acetate/acidic acid, arginine, and trehalose. In addition, the present invention relates to pharmaceutical formulations for a therapeutical antibody, preferably an IgG, said formulation comprising at least histidine, mannitol and/or succinate and trehalose. | 2015-06-04 |
20150150983 | Intra-articular Formulations and Methods for Treatment of Osteoarthritis - Intra-articular formulations and methods are provided for treating joint conditions, such as osteoarthritis. The formulations include an effective amount of recombinant human growth differentiation factor-5 (rhGDF-5) and an acidic vehicle, where the formulation is an intra-articular injection formulation. The formulations described herein can be used for treating joint conditions (e.g., osteoarthritis) via intra-articular injection in a subject in need thereof. | 2015-06-04 |
20150150984 | COMPOSITIONS OF PEGYLATED SOLUBLE TUMOR NECROSIS FACTOR RECEPTORS AND METHODS OF PREPARING - The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability. | 2015-06-04 |
20150150985 | SOLID PHARMACEUTICAL FORMULATION WITH DELAYED RELEASE - The invention relates to a solid pharmaceutical preparation with delayed release of the active ingredients which is suitable in particular for use in animals. | 2015-06-04 |
20150150986 | POLYMERIC DRUG DELIVERY SYSTEM FOR TREATING SURGICAL COMPLICATIONS - A composition comprising a polymer and at least one active agent, wherein the composition is formulated for topical application and shows thermally reversible behavior or inverse thermally reversible behavior. The active agent of the composition is an antimicrobial, an anti-inflammatory agent, anesthetic or mixtures thereof. A method of preparing the composition is also provided. | 2015-06-04 |
20150150987 | BIODEGRADABLE DRUG DELIVERY FOR HYDROPHOBIC COMPOSITIONS - A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethyl-ene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle or hydrophobic active principle such as medroxyprogesterone acetate, levonorgestrel, cyclosporine, progesterone or bupivacaine is disclosed. | 2015-06-04 |
20150150988 | In Situ Film-Forming Bioactive Solutions of Absorbable Multiblock Copolymers - An in situ film-forming methyl acetate-based solution of at least one absorbable, segmented block copolymer with amorphous and semi-crystalline segments contains at least one bioactive agent which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane. The solution can be applied (e.g., sprayed or swabbed) onto animal and human skin or accessible body cavities to prevent or treat one or more disorders preventable or treatable by the bioactive agent therein. | 2015-06-04 |